Trevena, Inc. (NASDAQ: TRVN) Completes Phase 3 Apollo Trials for Oliceridine, Says Athena Study on Track
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, on January 4 announced it had completed enrollment for its Phase 3 Apollo Pivotal Efficacy Trials of oliceridine for moderate to severe pain. Oliceridine (TRV 130) is Trevena’s lead product candidate. It was deemed “a breakthrough therapy by the U.S. Food and Drug Administration,” based on the results of earlier clinical trials, the company said (http://dtn.fm/5zmYr). “We are pleased to have completed enrollment in these important studies and to confirm that the Apollo trials remain on schedule to report top-line results in the first quarter of 2017,” Maxine Gowen, Ph.D., chief…